During the past 12 months, Chemomab Therapeutics's average Book Value per Share Growth Rate was -40.00% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -48.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 5 years, the highest 3-Year average Book Value per Share Growth Rate of Chemomab Therapeutics was 6.80% per year. The lowest was -48.90% per year. And the median was -21.05% per year.
Competitive Comparison of Chemomab Therapeutics's 3-Year Book Growth Rate
For the Biotechnology subindustry, Chemomab Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemomab Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Chemomab Therapeutics's 3-Year Book Growth Rate falls into.
Chemomab Therapeutics 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
Chemomab Therapeutics (NAS:CMMB) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Chemomab Therapeutics 3-Year Book Growth Rate Related Terms
Thank you for viewing the detailed overview of Chemomab Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CMMB has been successfully added to your